Mannatech, Incorporated - Common Stock (MTEX)
Healthcare › Medicinal Chemicals & Botanical Products
Price History
Feb 9, 2026 — May 11, 2026Investment Snapshot
- P/B of 1.37 — trading near book value
- Piotroski F-Score 2/9 — signs of financial weakness
- ROE of 24.1% — good return on equity
- Revenue declining 8% annually
Mannatech, Incorporated - Common Stock (MTEX) is a Healthcare company operating in Medicinal Chemicals & Botanical Products, listed on the NASDAQ , with a market capitalisation of $11 million . Key value metrics: P/B ratio 1.37, Piotroski F-Score 2 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Mannatech, Incorporated - Common Stock — Fundamental Analysis Summary
On financial health, MTEX shows a weak Piotroski F-Score of 2/9, a signal of deteriorating financial health, and strong return on equity of 24.1% (sector average: -20.6%), and manageable leverage with a debt-to-equity ratio of 0.42.
StockPik's composite Value Score for MTEX is 60/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
MTEX reports a high gross margin of 75.5% (sector average: 40.1%) and a modest operating margin of 0.8%.
MTEX shows revenue declining at 8% year-over-year, with earnings declining at 711%.
MTEX pays a high dividend yield of 8.8%.